D1 Capital Partners has led a $102m series D round for Inflammatix, whose existing shareholders include Stanford-StartX Fund.
Inflammatix, a US-based molecular diagnostics company based on research at Stanford University, closed a $102m series D round yesterday led by D1 Capital Partners.
OSF Healthcare Ventures, the investment arm of health system OSF Healthcare, also took part in the round, as did Northpond Ventures, Khosla Ventures and Think.Health.
Founded in 2016, Inflammatix is working on rapid diagnostic tests that detect a patient’s immune response to infections by analysing mRNA biomarkers using machine learning technology.
The tests…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
